Hologic Inc HOLX
We take great care to ensure that the data presented and summarized in this overview for HOLOGIC INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HOLX
View all-
Vanguard Group Inc Valley Forge, PA27MShares$1.95 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY23.1MShares$1.67 Billion0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD22.1MShares$1.6 Billion1.09% of portfolio
-
Morgan Stanley New York, NY10.9MShares$788 Million0.07% of portfolio
-
State Street Corp Boston, MA10.4MShares$755 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA5.59MShares$405 Million0.04% of portfolio
-
Victory Capital Management Inc4.89MShares$355 Million0.4% of portfolio
-
Mitsubishi Ufj Kokusai Asset Management Co., Ltd.4.27MShares$310 Million0.38% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.6MShares$261 Million0.08% of portfolio
-
Invesco Ltd. Atlanta, GA3.5MShares$254 Million0.06% of portfolio
Latest Institutional Activity in HOLX
Top Purchases
Top Sells
About HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Insider Transactions at HOLX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 13
2024
|
Brandon Schnittker Div. President, GYN Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-1.44%
|
$6,570
$73.65 P/Share
|
Dec 09
2024
|
Martin D Madaus Director |
BUY
Grant, award, or other acquisition
|
Direct |
342
+50.0%
|
-
|
Dec 04
2024
|
Essex D Mitchell Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
24,856
-47.06%
|
$1,889,056
$76.34 P/Share
|
Dec 04
2024
|
Essex D Mitchell Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,902
+11.47%
|
$1,282,512
$56.51 P/Share
|
Nov 14
2024
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,860
-0.55%
|
$528,220
$77.54 P/Share
|
Nov 14
2024
|
Brandon Schnittker Div. President, GYN Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-2.77%
|
$13,706
$77.54 P/Share
|
Nov 14
2024
|
Jan Verstreken Group President, International |
SELL
Payment of exercise price or tax liability
|
Direct |
630
-0.6%
|
$48,510
$77.54 P/Share
|
Nov 14
2024
|
Karleen Marie Oberton Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,332
-1.29%
|
$102,564
$77.54 P/Share
|
Nov 14
2024
|
Jennifer M Schneiders President, Diag. Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
507
-4.02%
|
$39,039
$77.54 P/Share
|
Nov 14
2024
|
John M. Griffin General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-0.61%
|
$86,240
$77.54 P/Share
|
Nov 14
2024
|
Essex D Mitchell Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,341
-4.29%
|
$103,257
$77.54 P/Share
|
Nov 14
2024
|
Benjamin Jordan Cohn Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
110
-0.97%
|
$8,470
$77.54 P/Share
|
Nov 14
2024
|
Erik S Anderson Div. Pres., Breast & Skeletal |
SELL
Payment of exercise price or tax liability
|
Direct |
390
-1.65%
|
$30,030
$77.54 P/Share
|
Nov 11
2024
|
Stephen P Macmillan Chairman, President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
39,677
+3.1%
|
-
|
Nov 11
2024
|
Brandon Schnittker Div. President, GYN Surgical |
BUY
Grant, award, or other acquisition
|
Direct |
2,834
+30.59%
|
-
|
Nov 11
2024
|
Jan Verstreken Group President, International |
BUY
Grant, award, or other acquisition
|
Direct |
6,298
+5.69%
|
-
|
Nov 11
2024
|
Karleen Marie Oberton Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,447
+8.37%
|
-
|
Nov 11
2024
|
Jennifer M Schneiders President, Diag. Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
6,298
+33.32%
|
-
|
Nov 11
2024
|
Essex D Mitchell Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,021
+26.07%
|
-
|
Nov 11
2024
|
Benjamin Jordan Cohn Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,180
+9.41%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 297K shares |
---|---|
Exercise of conversion of derivative security | 145K shares |
Open market or private sale | 198K shares |
---|---|
Payment of exercise price or tax liability | 124K shares |
Bona fide gift | 81.9K shares |